New hope for rare nerve disease: can a biologic drug cut steroid use?
NCT ID NCT07159893
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests a drug called inebilizumab combined with a fast steroid taper in 25 people newly diagnosed with neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease that attacks the optic nerves and spinal cord. The goal is to see if this approach can reduce the need for long-term steroids while controlling the disease and improving disability scores. Participants will be followed for relapses and changes in blood markers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Inebilizumab (a biologic drug) and prednisone (a steroid)
What this could lead to
If it works, this could help newly diagnosed NMOSD patients use less steroids while still controlling the disease, potentially reducing side effects from long-term steroid use.
What could go wrong
This is a very small, early-phase study with only 25 people, so results may not apply broadly. The drug may not reduce relapses or disability as hoped, and there are risks from both the biologic and steroid taper.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••